A Canadian group has just added a little more to our knowledge about the role of neoadjuvant hormone therapy in association with radiotherapy after first-line radical prostatectomy (RP).
Pai et al. have reported data from a retrospective analysis performed on 175 patients with clinically localized prostate cancer who were first treated with RP and who who subsequently received radiotherapy (dose range 50 Gy-68 Gy, which is still a slightly low dose range compared to the higher ranges observed normally today).
Twenty-two patients received adjuvant radiotherapy (ART), 57 received neoadjuvant androgen deprivation therapy (NADT) + ART, 15 received salvage radiation therapy (SRT), and 81 received NADT + SRT. Outcome was assessed by biochemical disease-free survival , prostate cancer-specific survival, and overall survival.
Biochemical disease-free survival at 5 years was observed in:
- 67 percent of ART patients
- 80 percent of NADT + ART patients
- 27 percent of SRT patients
- 62 percent of NADT + SRT patients
which would seem to suggest an overall benefit for patients who received NADT + ART compared to other options. However, it turned out that on multivariate analysis the only three independent predictive factors of improved biochemical disease-free survival were a PSA level ≤ 0.2 ng/ml before radiotherapy, a low Gleason score, and positive surgical margins. The patient’s age and his Gleason score were independent predictors of overall survival.
The authors conclude that:
- The pre-radiotherapy PSA level is an important predictor of outcome.
- NADT appears to benefit patients who presented with a pre-radiotherapy PSA level > 0.2 ng/ml, particularly for patients receiving SRT.
- NADT can be considered for patients receiving radiotherapy after RP who present with a high pre-radiotherapy PSA level, but may not be necessary for patients with a low PSA level.
Filed under: Management, Treatment, Uncategorized | Tagged: androgen deprivation therapy, neoadjuvant, radiotherapy, salvage


Search for new and
ongoing trials on the
CTAG PCa web site
